Results 201 to 210 of about 73,005 (301)
<i>Klebsiella pneumoniae</i> vaccines: Evolving the blueprint from traditional platforms to mucosal and nanoscale delivery. [PDF]
Hu J, Xie Y, Guan W, Huang L, Li X.
europepmc +1 more source
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan +3 more
wiley +1 more source
Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol. [PDF]
Paganotti Vicentine M +25 more
europepmc +1 more source
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović +11 more
wiley +1 more source
Creating unimolecular multivalent diversity in protein conjugates via the Passerini multicomponent bioconjugation with isocyanoproteins. [PDF]
Humpierre AR +11 more
europepmc +1 more source
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity [PDF]
Ciorba, Matthew A +9 more
core +1 more source
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
A scalable purification strategy using hydroxyl (OH) monolithic chromatography enables efficient isolation and direct concentration of MSC‐EVs from adherent and microcarrier‐based upstreams. This approach supports process scale‐up while ensuring high purity suitable for therapeutic EV manufacturing.
Katja Vrabec +8 more
wiley +1 more source

